PROVECTUS BIOPHARMACEUTICALS, INC. 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Feb 28, 2014
Insider Transaction Report
Form 4
CULPEPPER PETER R
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2014-02-26$1.10/sh+68,624$75,486→ 1,012,332 total - Exercise/Conversion
Common Stock
2014-02-26$1.10/sh+121,000$133,100→ 121,000 total(indirect: By 401(k)) - Exercise/Conversion
Stock Option (right to buy)
2014-02-26+189,624→ 0 totalExercise: $1.10From: 2004-02-26Exp: 2014-02-26→ Common Stock (189,624 underlying)